Study of olomorasib for KRAS G12C-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer with a KRAS G12C mutation.
- Your cancer must be at a certain stage (II, III, or IIIB) and may or may not be surgically removable.
- You must have an ECOG performance status of 0 or 1, meaning you are fully active or only limited in physically strenuous activity.
- You must be able to swallow pills.
- You must not have had a complete response to prior treatment (for one part of the trial).
- You must not have had an allergic reaction or severe side effects from previous immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This trial is testing an oral medication called olomorasib for people with advanced colorectal cancer that has a specific gene change (KRAS G12C). It may be a good option if you have not yet had treatment for cancer that has spread.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.